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The mild neurological impairment rate was 0.13 in 100,000.
The rate of acute complications only was 1.23 in 100,000.
The rate of asymptomatic diagnosis was 0.63 in 100,000. The percentage of symptomatic cases undiagnosed was 0%. The best estimate was 37%.
The MCAD incidence post-screening was 4.4 in 100,000.
The sensitivity of MS/MS was 90% and the specificity was 99.9%.
The mortality reduction with screening was 60%. The best estimate was 90%.
The life expectancy with severe neurological impairment was 65 years.
The quality of life with severe neurological impairment was 0.06.
The quality of life with mild neurological impairment was 0.67.
Various values (not reported) were used for the age-adjusted QALYs.
Methods used to derive estimates of effectiveness
The authors made some assumptions to identify the most conservative scenario for the study intervention.
Estimates of effectiveness and key assumptions
The authors assumed that all undiagnosed MCAD cases in the absence of screening were asymptomatic. They also assumed that the distribution of outcomes for Wisconsin cases diagnosed in the absence of screening, with death and neurological impairment occurring at one year of age, was similar. Also, further morbidity or mortality later in life relative to a prior metabolic decompensation was excluded. It was also assumed that infants with asymptomatic MCAD would have a normal life expectancy.
Measure of benefits used in the economic analysis
The QALYs were used as the benefit measure in the economic analysis. A 3% annual discount rate was applied since the time horizon of the analysis was lifetime. The quality of life weights used to calculate QALYs for mild neurological impairment were based on ratings of this health state by teenagers formerly of extremely low birth weight. The valuation tool was the standard gamble. The weights for severe neurological impairment were based on the Health Utility Index 3 scores for patients with severe dementia. The QALY values were then adjusted according to agespecific weights, as described by Erickson et al. (see Other Publications of Related Interest).
Direct costs
A 3% discount rate was used since the lifetime costs were estimated in the analysis. The unit costs were reported, but the quantities of resource consumption were not and would, therefore, have to be inferred from the model. The health service costs included in the economic evaluation were for the screening test, positive test confirmation, carnitine supplements to age 18, follow-up and routine hospital admissions. The screening costs were for the MS/MS instrument, personnel, consumables, data management operations, departmental indirect expenses, and laboratory overhead and programme start-up. The follow-up costs included testing, visits and staff time to age 18. The cost-savings were calculated on the basis of the avoided costs of neurological impairment and medical costs of fatal and acutely ill cases. The cost/resource boundary adopted was not explicitly stated, but it was probably that of the health service. The hospital costs were estimated using charge data from the Healthcare Cost and Utilisation Project, adjusted by a national cost-to-charge ratio of 0.6. Other costs were derived from the Wisconsin Newborn Screening Program. The data on resource consumption were derived from assumptions and published studies. All of the costs were inflated to 2001 prices using the Consumer Price Index.
